|

Lupus Clinical Trials in Houston, TX

24 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusPhase 2/3<1 mi
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusPhase 3<1 mi
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusPhase 3<1 mi
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus ErythematosusPhase 3<1 mi
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)Phase 4<1 mi
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisPhase 3<1 mi
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)Phase 2<1 mi
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsPhase 3<1 mi
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)Phase 1/2<1 mi
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VPhase 2<1 mi
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) StudyPhase 2<1 mi
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)Phase 2<1 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Phase 1<1 mi
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusPhase 1/2<1 mi
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesPhase 2<1 mi
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors—<1 mi
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune DisordersPhase 1/2<1 mi
A Study of Obexelimab in Patients With Systemic Lupus ErythematosusPhase 2<1 mi
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusPhase 2<1 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable CancerPhase 1<1 mi
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).Phase 37 mi
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusPhase 122 mi
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisPhase 347 mi
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusPhase 347 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.